PEP-Therapy is a IND-stage medical biotechnology company developing peptides as targeted therapies for severe diseases, with an initial focus on oncology.
Year of creation: 2014
Line of business: Biotechnology
Institut Curie: Behind the technology and R&D partner
PEP-Therapy has developed a proprietary Cell Penetrating and Interfering Peptides (CP&IP) technology for the development of its therapeutic products. These innovative peptides penetrate cells and then specifically block relevant intracellular protein-protein interactions, thus inhibiting key pathological mechanisms.
Two major innovations have been combined in a single bi-functional peptide to target efficiently and accurately key cellular mechanisms involved in pathologies:
Optimized Cell Penetrating Peptides (CPP), as a "shuttle" to deliver drugs pharmaceutically active peptides into the cell and also into specific organelles;
Short Interfering peptides specifically designed to target relevant protein/protein interactions, thus blocking key mechanisms of diseases, with no effect on other physiological functions of the two proteins.
The company's lead product and first CP&IP-based product, PEP-010, is an anti-cancer agent and is entering Phase Ia/b clinical trial in Q1 2021 in partnership with two leading European cancer hospitals, Institut Curie and Gustave Roussy.
Oncology & other severe diseases.
More about PEP-Therapy:
- PEP-Therapy raises €1.2 M to advance its therapeutic peptides